



## Mechanisms and Novel Therapeutic Approaches for Gliomas

Guest Editor:

**Dr. Maria V.  
Chatziathanasiadou**

Honorary Research Associate,  
Department of Brain Sciences,  
Faculty of Medicine, Imperial  
College London, London, UK

Deadline for manuscript  
submissions:

**closed (31 July 2025)**

### Message from the Guest Editor

Gliomas, the most common type of primary malignant brain tumour, present significant clinical challenges. This is mainly due to their invasive nature, intratumour heterogeneity, immunosuppressive microenvironment, and the presence of the blood–brain barrier. Little progress has been achieved in glioma treatment over the last few decades, while the main therapeutic options are surgery, radiotherapy, and chemotherapy. Thus, there is an imperative need to deepen our current understanding of glioma mechanisms and develop cutting-edge therapeutic strategies.

This Special Issue aims to cover molecular and cellular glioma mechanisms, including molecular markers, signaling, tumour landscape, cell crosstalk, and immunity, as well as novel therapeutic approaches, such as metabolic therapies, immunotherapies, newly designed and repurposed drugs, and combination treatments.

We also welcome review manuscripts that present recently discovered molecular markers, therapeutic targets, tumour landscape characteristics, or innovative therapies from preclinical studies and clinical trials.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)